Results 221 to 230 of about 22,548 (354)

Editorial: Exploring 'omic' biomarkers in animal production and reproduction. [PDF]

open access: yesFront Vet Sci
Aponte PM   +2 more
europepmc   +1 more source

Epigallocatechin‐3‐Gallate Suppresses Glioma by Targeting Integrin αvβ3/FAK/ERK Signaling Axis and Matrix Metalloproteinases

open access: yesPhytotherapy Research, EarlyView.
EGCG suppresses glioma progression by targeting integrin αvβ3/FAK/ERK signaling and inhibiting MMP‐2/MMP‐9‐mediated ECM degradation, thereby blocking proliferation, migration, invasion, and promoting apoptosis. ABSTRACT Epigallocatechin‐3‐gallate (EGCG), the most abundant and biologically active catechin in green tea, has been widely reported to ...
Rui Sun   +7 more
wiley   +1 more source

Retinoblastoma gene‐independent G1 phase arrest by flavone, phosphatidylinositol 3‐kinase inhibitor, and histone deacetylase inhibitor [PDF]

open access: bronze, 2012
Mitsuhiro Tomosugi   +7 more
openalex   +1 more source

A Combined Colon Organoid‐Sensory Neuron Model Reveals Epithelial Contribution to Moringin Efficacy Against Painful Inflammatory Bowel Disease

open access: yesPhytotherapy Research, EarlyView.
Experimental workflow and main findings of the study. ABSTRACT Visceral pain is a major symptom of inflammatory bowel diseases (IBDs), requiring effective treatment strategies. Gut epithelium, beyond maintaining barrier integrity and microbiota homeostasis, modulates neurosensorial circuitries, influencing visceral sensitivity.
Francesco Margiotta   +7 more
wiley   +1 more source

Reduced lipid metabolite abundance in human pancreatic cancer and matched serum samples following neoadjuvant FOLFIRINOX treatment. [PDF]

open access: yesMetabolomics
Amrutkar M   +6 more
europepmc   +1 more source

Novel Therapeutics for Chronic Obstructive Pulmonary Disease: From Empirical Bronchodilation to Precision Medicine

open access: yesRespirology, EarlyView.
ABSTRACT Chronic obstructive pulmonary disease (COPD) remains the third leading cause of death worldwide, and conventional bronchodilator‐based therapies have limited efficacy in preventing exacerbations and disease progression. The 2024–2026 period represents a historic inflection point: three mechanistically distinct agents received Food and Drug ...
Naoya Fujino, Hisatoshi Sugiura
wiley   +1 more source

Home - About - Disclaimer - Privacy